The $257.6M cash position removes near-term financing risk, but the company remains pre-revenue with no approved products. The stock's next major catalyst is initiation of the denifanstat Phase 3 acne trial in H2 2026 — monitor for patient enrollment updates or FDA regulatory feedback. Insider selling of $719K over the prior 30 days warrants caution but is relatively modest given the $591M market cap.
Price Chart
Executive Summary
Sagimet Biosciences reported Q2 2026 financial results, highlighting a net loss of $13.95 million ($0.26 per share) versus $10.39 million ($0.32 per share) in Q2 2025. The company ended the quarter with $257.6 million in cash, bolstered by a $175 million equity financing in April 2026, which funds operations through 2028. Key clinical catalysts include an upcoming Phase 3 trial for denifanstat in acne and ongoing Phase 1 trials for TVB-3567, positioning the stock as a binary event play on pipeline execution.
Key Financial Metrics
Key Facts
- Q2 2026 net loss of $14.0 million vs $10.4 million in Q2 2025; net loss per share of $0.26 vs $0.32
- Cash, cash equivalents and marketable securities: $257.6 million as of June 30, 2026, up from $113.1 million at Dec 31, 2025
- Completed $175 million equity financing in April 2026
- Phase 3 denifanstat acne trial on track for H2 2026; IND opened in July 2026
- Phase 1 TVB-3567 trial ongoing; Phase 2 initiation targeted before end of 2026
- Added to Russell 3000 and Russell 2000 indexes effective June 29, 2026
- Denifanstat met all primary/secondary endpoints in partner Ascletis' Phase 3 China trial; NDA accepted by NMPA December 2025
Financial Impact
Q2 2026 net loss $14.0 million; cash burn $18.5M (R&D) + $9.0M (G&A) in H1 2026; cash runway through 2028
Risk Factors
- Clinical-stage biopharma with no approved products or revenue; entirely dependent on pipeline trial outcomes
- Phase 3 denifanstat trial may fail to replicate Ascletis' China results in US population
- Insider selling of $719K in past 30 days raises potential confidence concerns
- Dilution from $175M April 2026 equity offering (29.2M shares at $6.00) impacts per-share metrics
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-343446 |
| Document: d36435dex992.htm | 0001193125-26-343446 |
| Document: d36435d8k.htm | 0001193125-26-343446 |
| Document: 0001193125-26-343446-index-headers.html | 0001193125-26-343446 |
| Document: 0001193125-26-343446-index.html | 0001193125-26-343446 |
| Document: 0001193125-26-343446.txt | 0001193125-26-343446 |
| 8-K Data (Synthetic) | 0001193125-26-343446 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $9.95 $9.58 | ▼ −3.72% | ▼ −3.20% | $9.58 (−3.72%) |
Oct 7, 2026 19d ago | SC 13G | $8.92 $8.93 | ▲ +0.11% | ▼ −0.49% | $9.58 (+7.40%) |
Oct 1, 2026 25d ago | Press Release | $9.14 $9.03 | ▲ +1.20% | ▲ +1.88% | $9.58 (−4.81%) |
Sep 30, 2026 26d ago | Press Release | $9.88 $9.37 | ▲ +5.16% | ▲ +5.34% | $9.58 (+3.04%) |
Sep 30, 2026 26d ago | 8-K | $9.88 $9.37 | ▼ −5.16% | ▼ −5.34% | $9.58 (−3.04%) |
Sep 22, 2026 4w ago | Institutional Cluster | $11.09 $10.42 | ▼ −6.04% | ▼ −5.32% | $9.58 (−13.62%) |
Aug 25, 2026 8w ago | Press Release | $10.29 $10.86 | ▲ +5.54% | ▲ +5.52% | $9.58 (−6.90%) |
Aug 11, 2026 10w ago | 8-K | $9.52 $9.39 | ▼ −1.37% | ▼ −1.62% | $9.58 (+0.63%) |
Aug 11, 2026 10w ago | Press Release | $9.52 $9.39 | ▼ −1.37% | ▼ −1.62% | $9.58 (+0.63%) |
Jul 22, 2026 13w ago | Insider Cluster | $7.01 $7.07 | ▲ +0.86% | ▲ +0.75% | $9.58 (+36.66%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers